Pierre Vandepapelière has been Amyl's co-founder, CEO, and CMO since 2020. Previously, he was CEO of Imcyse from 2014 to 2019, transforming the company into a rapidly growing biotech and raising €35M in Series B funding. During the COVID-19 pandemic, he contributed to several vaccine projects, including creating Astrivax. Pierre has also held leadership roles at Neovacs and GlaxoSmithKline. He holds a medical degree and a PhD. In his spare time, Pierre enjoys sailing, photography, and birdwatching.

Before joining Amyl, Damien worked as a Project Lead at Pharnext, focusing on neurodegenerative diseases, including Parkinson’s, Alzheimer’s, and ALS. He co-founded and served as CSO of Encefa for eight years, leading the development of a monoclonal anti-CD38 antibody for ALS. Damien holds an MSc in Biochemistry and Genetics from Agrocampus Rennes and a PhD in Neurosciences from Paris Sorbonne. He is currently the CSO of Amyl. Damien is also a fan of hard rock and metal music.

Julie joined Amyl Therapeutics as R&D Director in early 2023. She has over 10 years of experience in scientific and management roles in the biotech sector. After her thesis related to neurodegeneration, Julie developed bioassays at GSK Vaccines and became a project manager focused on clinical research disclosure. At Thermo Fisher Scientific, she led upstream process development for viral vectors. Julie holds a PhD in Biological Sciences from UCLouvain, Belgium. She is leading the R&D team with fervor, while in her private life, she likes to unwind in close contact with nature.

Christophe holds three Master's degrees in Law, European Law, and Tax Management. He is a Chartered Accountant and Tax Advisor with expertise in corporate governance. Christophe began his career as an M&A lawyer in Brussels before moving to a role as a Tax Advisor at KPMG Belgium. He later founded Financial Way, where he served as CEO and CFO for more than 15 life science startups. Passionate about wine, skiing, and tranquility, Christophe even completed a marathon and enjoys long commutes by train or bike, preferring them over driving.

Koen Vanhalst holds a PhD in Biotechnology from the University of Ghent and has experience as an Examiner at the European Patent Office. He qualified as a European Patent Attorney in 2009 and a Belgian Patent Attorney in 2011, becoming a partner at De Clercq & Partners in 2017. In 2023, he earned a Certificate in Patent Litigation in Europe. Koen teaches Intellectual Property at Ghent Universityand is active in organizations like AIPPI Belgium and the Belgian Council for Intellectual Property. At Amyl, he develops IP strategy while enjoying traveland cultural exploration in his free time.

Karine worked for over 20 years in the R&D department at GSK Vaccines, holding key positions such as Vaccine Project Leader and Head of Discovery Performance Unit at the GSK RD Center in Italy. She has a PhD in Biochemistry from Liege University, specializing in Protein Engineering. From 2021 to 2024, she served as CSO of Amyl, overseeing preclinical development. She now serves as a Strategic Advisor. Karine enjoys spending time with her family, attending classic and rock concerts, and taking trips in her van to explore nature.